Clinical Trial Update: A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Tremelimumab combined with the anti-PD-L1 antibody durvalumab (MEDI4736) for malignant mesothelioma, including pleural and peri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Mesothelioma
• Pleural Mesothelioma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Italian Network for Tumor Biotherapy Foundation | Conditions: Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Status: UNKNOWN